Amgen’s Breakthrough Blincyto Clears FDA At Breakneck Pace, But With REMS Attached
This article was originally published in The Pink Sheet Daily
Executive Summary
The big biotech’s blinatumomab gains accelerated approval to treat a rare form of ALL. The breakthrough therapy does have a REMS on serious risks and administration concerns.